EBS - Emergent BioSolutions Reports Q4 Results Amends Credit Agreement | Benzinga
Emergent Biosolutions Inc (NYSE:EBS) shares are trading higher after the company amended its existing credit agreement and reported its fourth-quarter financial results. Here's a look at the details.
The Details: Emergent BioSolutions reported quarterly losses of 77 cents per share, missing the analyst consensus estimate of losses of 19 cents per share.
Quarterly sales came in at $276.6 million which missed the analyst consensus estimate of $293.533 million and is a 16.36% decrease from the same period last year.
Quarterly revenues from Narcan (naloxone HCl) Nasal Spray increased $19.9 million, or 22% year-over-year. The increase was primarily driven by ...